他汀类药物在糖尿病前期或2型糖尿病合并非酒精性脂肪性肝炎患者中的肝脏安全性:一项随机试验的事后分析
该事后分析基于评估吡格列酮对比安慰剂治疗非酒精性脂肪性肝炎(NASH)的随机对照试验,纳入101例经活检证实的NASH合并糖尿病前期/2型糖尿病患者,随访至36个月。结果显示他汀使用者和非使用者随访期间转氨酶升高≥2倍的患者数相同(各4例),新启用他汀并接受安慰剂者的肝脏组织学或肝脏胰岛素抵抗无变化。作者结论为他汀治疗在该人群中是安全的,应鼓励使用。
要点
- 在他汀使用者和非使用者中,随访期间血浆转氨酶升高≥2倍的患者数相同,均为4例。
- 新启用他汀并接受安慰剂的患者,肝脏组织学或肝脏胰岛素抵抗未见变化。
- 作者结论为他汀治疗在糖尿病前期/2型糖尿病合并NASH患者中是安全的,应鼓励使用。
核心结论
- 他汀治疗在糖尿病前期/2型糖尿病合并NASH患者中是安全的。
- 鉴于该人群心血管风险高,应鼓励他汀治疗。
研究设计与样本
- 研究设计为评估吡格列酮对比安慰剂治疗NASH的随机对照试验的事后分析。
- 共纳入101例经活检证实的NASH合并糖尿病前期/2型糖尿病患者,其中86例接受他汀治疗,随访至36个月。
- 干预包括口服葡萄糖耐量试验和经皮肝活检(基线、第18个月和第36个月),以及肝脏磁共振波谱和高胰岛素-正葡萄糖钳夹(基线和第18个月)。
主要发现
- 入组时仅37%的患者接受他汀治疗,尽管其心血管风险高。
- 他汀非使用者基线血浆丙氨酸氨基转移酶水平较高,但基线肝脏疾病组织学严重程度相似。
- 在他汀使用者和非使用者中,随访期间血浆转氨酶升高≥2倍的患者数相同(各4例)。
- 1例他汀非使用者因此转氨酶升高而退出研究,其余所有病例未经任何积极措施即恢复正常。
- 新启用他汀并接受安慰剂的患者,肝脏组织学或肝脏胰岛素抵抗未见变化。
临床怎么用
- 原文结论指出他汀治疗在糖尿病前期/2型糖尿病合并NASH患者中是安全的,鉴于其心血管风险高,应鼓励他汀治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. OBJECTIVE: To prospectively assess the long-term safety of statins in patients with prediabetes/type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH). DESIGN: Post hoc analysis of statin use during a randomized, controlled trial assessing pioglitazone vs placebo for NASH. PATIENTS: A total of 101 patients (86 receiving statins) with biopsy-proven NASH and prediabetes/T2DM were followed for up to 36 months. INTERVENTIONS: Oral glucose tolerance test and percutaneous liver biopsy (baseline, month 18, and month 36); liver magnetic resonance spectroscopy and euglycemic insulin clamp (baseline and month 18). MAIN OUTCOME MEASURES: Histologic and biochemical safety of statin use among patients with NASH. RESULTS: Only 37% of patients were receiving statins at enrollment despite their high cardiovascular risk. Statin nonusers had higher plasma alanine aminotransferase levels but similar histologic severity of liver disease at baseline. In both statin users and nonusers, the same number of patients (n = 4) had a twofold or greater increase in plasma aminotransferases during follow-up. One statin nonuser was discontinued from the study because of this elevation. Values returned to normal without any active measure in all other cases. No changes on liver histology or hepatic insulin resistance were observed in patients with NASH newly started on a statin and receiving placebo during the main study. CONCLUSIONS: Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population.
引用
- Bril F, Portillo Sanchez P, Lomonaco R, et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. J Clin Endocrinol Metab. 2017. PMID: 28575232. doi:10.1210/jc.2017-00867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。